Skip to main content
IntoCell, Inc. logo

IntoCell, Inc. — Investor Relations & Filings

Ticker · 287840 ISIN · KR7287840003 KO Professional, scientific and technical activities
Open in API
Filings indexed 48 across all filing types
Latest filing 2026-03-26 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 287840

About IntoCell, Inc.

https://intocell.com/

IntoCell, Inc. is a biotechnology company specializing in the research and development of platform technologies for Antibody-Drug Conjugates (ADCs). The company's core focus is on creating novel biopharmaceuticals, primarily for oncology applications. IntoCell develops proprietary technologies, including its OHPAS™ linker and Payload Modification Technology (PMT™), which are designed to improve the stability, efficacy, and safety of ADC therapeutics. The company advances its own drug pipeline and also collaborates with other pharmaceutical companies through technology transfer and partnership agreements to commercialize its ADC platforms.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory report filed with the Korean Financial Services Commission/KRX titled “주식매수선택권 부여에 관한 신고” (“Notification on Grant of Stock Options”). It details the number of options granted, exercise period, exercise price, fair‐value assumptions, grant basis under the charter, and lists grantees (executives and employees). This is not an earnings release, management change, or AGM material; rather it announces a capital‐related action (grant of stock options that will lead to future share issuance). Under our taxonomy, this constitutes a Share Issue/Capital Change announcement (SHA).
2026-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is the detailed results of a 정기주주총회 (Annual General Meeting) held on 2026-03-26, showing voting outcomes, approval of financial statements, director elections, and exact voting percentages per agenda item. This aligns with “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-03-26 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is titled '사업보고서' (Business Report) for the 11th fiscal year (2025), covering the period from 2025-01-01 to 2025-12-31. It contains detailed sections on company overview, business operations, capital changes, and financial data. This structure corresponds to the standard Korean Annual Report (10-K equivalent). FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and details regarding the external auditor. While it contains financial data, it is a summary disclosure of the audit results rather than the full annual report (10-K) or a standalone audit report (AR). In the context of Korean regulatory filings (DART/KIND), this specific format is a standard regulatory announcement of the audit report's submission. Given the definitions provided, it fits best as a Regulatory Filing (RNS) as it serves as an official notice of the audit report's availability and key findings. FY 2025
2026-03-18 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains details about the meeting agenda, board/auditor compensation, and proposed changes to the articles of incorporation. This falls under the category of Proxy Solicitation & Information Statement.
2026-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for IntoCell, Inc. It details the agenda for the 11th Annual General Meeting, including financial statement approval, director appointments, and stock option grants. While it contains financial data (financial statements), this is standard practice for proxy materials to inform shareholders before a vote. It is not an Annual Report (10-K) or an Earnings Release, but rather a solicitation of shareholder action for the upcoming meeting.
2026-03-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.